March 8th 2024
In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.
February 3rd 2024
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Avelumab/Axitinib Approved by FDA for Frontline Treatment of RCC
May 15th 2019The combination of avelumab (Bavencio) and axitinib (Inlyta) has been approved by the FDA for the frontline treatment of patients with advanced renal cell carcinoma, based on findings from the phase III JAVELIN Renal 101 trial.
Read More
Kessler Shares Her Perspective on Sequencing Therapies in Prostate Cancer
May 9th 2019Elizabeth Kessler, MD, explained to a group of physicians in a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation the treatment considerations and decisions she makes when seeing a patient with prostate cancer in the clinic.
Read More
Despite Early Trial Closure, 177LuPSMA-617 Demonstrates Safety and Improved PFS in mCRPC
May 6th 2019In a preliminary analysis of a phase II trial, the radiolabeled small molecule, <sup>177</sup>LuPSMA-617, demonstrated a biochemical progression-free survival of 4 months in a cohort of 64 men with metastatic castrate-resistant prostate cancer.
Read More
Phase III Trial Launches to Investigate Cabozantinib Plus Nivolumab/Ipilimumab in Frontline RCC
May 6th 2019A phase III clinical trial evaluating cabozantinib (Cabometyx) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with previously untreated advanced renal cell carcinoma has been initiated, according to Exelixis, the developer of cabozantinib.
Read More
Darolutamide Granted Priority Review by FDA for Treatment of Nonmetastatic CRPC
April 29th 2019A new drug application seeking the approval of darolutamide as a treatment for patients with nonmetastatic castration-resistant prostate cancer has been granted a priority review designation by the FDA.
Read More
Immunotherapy and TKI Combinations Are Emerging as Standard of Care in Advanced RCC
April 18th 2019The results of several studies presented at the 2019 Genitourinary Cancers Symposium confirmed that the combination of PD-1/PD-L1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway was superior to VEGF inhibitors alone in patients with clear cell renal cell carcinoma, which accounts for about 70% of patients with kidney cancer.
Read More
Sipuleucel-T Shows Potential With New Trial Data, But Questions Regarding Clinical Relevance Remain
April 15th 2019Since the approval of sipuleucel-T for the treatment of minimally symptomatic metastatic castration-resistant prostate cancer in 2010, barriers to administration and the approval of competing drugs has tampered wide adoption of its use.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
Safety, Efficacy Results Bolster the Use of LuPSMA in Advanced Prostate Cancer
April 3rd 2019The novel targeted radiation therapy, lutetium 177 prostate-specific membrane antigen, demonstrated safety and therapeutic efficacy in 22 patients with metastatic castration-resistant prostate cancer, based on findings presented during the ESMO 2019 International Congress on Targeted Anticancer Therapies.
Read More
Dr. Posadas Discusses Darolutamide in Castration-Resistant Prostate Cancer
March 29th 2019Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
Watch
NCCN Guidelines for Advanced RCC Could See Changes as More Frontline Data Emerge
March 26th 2019Under the 2019 update to the National Comprehensive Cancer Network guidelines, the recommendation on the management of advanced clear cell renal cell carcinoma has undergone a major shift in defining the risk category used to define preferred and alternative first-line treatments.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Treatment Landscape Moves Toward Personalized Medicine for Castration-Resistant Prostate Cancer
March 6th 2019According to Raoul S. Concepcion, MD, FACS, the field of castration-resistant prostate cancer continues to progress with new treatment options; next steps include tailoring these new treatment strategies to individual patients.
Read More
Darolutamide Submitted for FDA Approval in Nonmetastatic CRPC
February 27th 2019Based on findings from the phase III ARAMIS trial, a new drug application for darolutamide has been submitted to the FDA seeking the investigational agent's approval as a treatment for patients with nonmetastatic castration-resistant prostate cancer, according to the codevelopers of the investigational agent, Bayer and Orion Corporation.<br />
Read More
Encouraging Activity Seen With Pembrolizumab in Non-Clear Cell RCC
February 18th 2019First-line treatment with single-agent pembrolizumab induced a 24.8% overall response rate in patients with non-clear cell renal cell carcinoma, according to findings from cohort B of the phase II KEYNOTE-427 trial that were presented during the 2019 Genitourinary Cancers Symposium.<br />
Read More
Pembrolizumab/Cabozantinib Combo Active in Metastatic RCC
February 17th 2019According to phase I findings from a dose-escalation cohort presented during the 2019 Genitourinary Cancers Symposium, the combination of pembrolizumab and cabozantinib demonstrated antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their approved doses for this indication.
Read More